The Company recently confirmed that the preliminary HLA prevalence, safety, and immune response data in FLAMINGO-01 patients is trending as expected in both HLA-A*02 and non-HLA-A*02 arms. The non-HLA ...

Collaboration to apply Lunit’s AI technologies across NCI’s broad spectrum of cancer studies, aiming to accelerate personalized cancer ...

Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 ...

The Trump administration's cuts to the National Institutes of Health has some worried about stalls in research and medicine.

An episode of the "Joe Rogan Experience" podcast, seen by more than 10 million, appears to have reignited interest in the ...

UPMC Hillman Cancer Center in central Pennsylvania has approximately 40,000 patient visits for medical oncology and infusion ...

New York City-based Weill Cornell has established a cancer research collaborative to explore ways to improve the ...

Karen Knudsen, PhD, has been appointed CEO of San Francisco-based Parker Institute for Cancer Immunotherapy. Dr. Knudsen previously served as CEO for both the American Cancer Society and ACS Cancer ...

Yunu, creator of the industry’s first end-to-end clinical trial imaging workflow platform supporting sites, CROs and pharma, ...

Misinformation about ivermectin as a cancer treatment is on the rise, with social media and public figures fueling false ...

The long-term impact of disruptions in oncology care during the COVID-19 pandemic will become more apparent in the coming years, according to Dan Nardi, MS, of Reimagine Care.

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...